- Report
- December 2025
- 369 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 369 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 486 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 377 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 288 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 341 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 380 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 375 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 553 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 383 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 476 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 141 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 466 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 565 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 283 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 673 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 676 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 392 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 553 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- December 2025
- 179 Pages
Global
From €5166EUR$5,850USD£4,519GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more